Medtronic Enters Distribution Agreement with Merit Medical
Medtronic (MDT) announced that it has entered into a distribution agreement with Merit Medical Systems (MMSI), to offer FDA-cleared ViaVerte, a minimally invasive and implant free basivertebral nerve ablation system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain. This agreement continues Medtronic's momentum in executing on strategic deals that strengthen the company's leadership within its core franchises and expands an ongoing relationship between Medtronic and Merit.
Trade with 70% Backtested Accuracy
Analyst Views on MDT
About MDT
About the author

- FDA Approval for New Indication: Medtronic's OmniaSecure™ defibrillation lead has received FDA approval for placement in the left bundle branch area, supporting conduction system pacing and enhancing patient outcomes, marking a significant innovation in cardiac medical technology.
- Market Leadership: As the smallest diameter defibrillation lead on the market (4.7 French), the OmniaSecure™ is suitable for both adults and pediatric patients aged 12 and up, further broadening Medtronic's customer base and enhancing its competitive edge.
- Clinical Trial Support: Data from the global LEADR LBBAP trial shows a 100% defibrillation success rate at implant and a low major complication rate of 2.1% at three months, providing strong clinical evidence for its safety and effectiveness.
- Product Portfolio Expansion: This approval enriches Medtronic's portfolio of lumenless leads and accessories, strengthening its market position in conduction system pacing and is expected to drive future sales growth and technology applications.
- Impact of Crude Prices: Oil drillers and energy stocks have seen significant gains this year due to rising crude prices.
- Geopolitical Factors: The surge in crude prices is attributed to the ongoing war in Iran and concerns over supply constraints.
- Revised Guidance: Medtronic PLC has updated its fiscal year 2026 non-GAAP earnings per share guidance.
- Earnings Range: The new guidance estimates earnings per share to be between $5.50 and $5.54.
- Exclusive Distribution Agreement: Medtronic has signed an exclusive agreement with Merit Medical Systems to launch the FDA-approved ViaVerte system, which is the first BVNA system with a physician-controlled steerable mechanism aimed at treating chronic vertebrogenic lower back pain, significantly enhancing treatment options for patients.
- Product Innovation: The unique design of the ViaVerte system allows physicians to precisely target the basivertebral nerve, thereby improving treatment outcomes and further solidifying Medtronic's leadership in the pain intervention space while providing more effective solutions for chronic pain patients.
- Strengthened Strategic Partnership: This agreement not only expands Medtronic's pain intervention product portfolio but also deepens the ongoing collaboration with Merit, which currently supplies Medtronic with Kyphon Xpander Inflation Syringes and Kyphon KyphoFlex unipedicular steerable balloon catheters used in balloon kyphoplasty procedures.
- Market Impact: By introducing the ViaVerte system, Medtronic enhances its competitiveness in the chronic pain treatment market, which is expected to attract more patients to its innovative treatment options, thereby driving continued growth in the medical technology sector.

Agreement Announcement: Medtronic has entered into an agreement to offer a new treatment for chronic vertebrogenic lower back pain.
FDA Clearance: The treatment involves the use of the FDA-cleared VERTEX™ system, which is designed for ablation of nerve tissue.
- FDA Expanded Approval: Medtronic's OmniaSecure defibrillation lead has received FDA approval for placement in the left bundle branch area, enabling conduction system pacing that closely mimics the heart's natural electrical activity, thereby improving patient treatment outcomes.
- Clinical Trial Support: This approval is backed by data from the global LEADR LBBAP trial, which demonstrated the lead's safety and effectiveness, further enhancing Medtronic's technological edge in cardiac treatment.
- Product Innovation: The OmniaSecure lead is the first defibrillation lead approved for placement in the left bundle branch area, with a diameter of only 4.7 French (1.66 mm), making it the smallest defibrillation lead available, and it is suitable for patients aged 12 and older.
- Market Outlook: This expanded indication enriches Medtronic's portfolio of conduction system pacing technologies, which is expected to drive further growth in the cardiac treatment market, despite Medtronic's stock closing down 0.82%.









